Allogeneic ‘off‐the‐shelf’ SARS‐CoV‐2‐specific adoptive T‐cell therapy for refractory viral infection and end organ disease

Abstract Objectives Despite the effective roll‐out of COVID‐19 vaccines, immunocompromised patients have a higher risk of morbidity and mortality following SARS‐CoV‐2 infection. Allogeneic adoptive T‐cell immunotherapy is now established as an effective approach to treat viral diseases in immunocomp...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Andrea S Henden, Katie E Lineburg, Archana Panikkar, Arushi Mahajan, Ricky Nelles, Emma Wright, Pauline Crooks, Jyothy Raju, Laetitia Le Texier, Srividhya Swaminathan, Leone Beagley, Shannon Best, Matthew Solomon, Hilary Reddiex, Glen Kennedy, Siok‐Keen Tey, Michelle A Neller, Rajiv Khanna, Corey Smith
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Wiley 2025-01-01
سلاسل:	Clinical & Translational Immunology
الموضوعات:	COVID‐19 immunocompromised SARS‐CoV‐2 VST therapy
الوصول للمادة أونلاين:	https://doi.org/10.1002/cti2.70038
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!